Clinical comprehensive evaluation on 49 lipid-lowering drugs in Liaoning province
- VernacularTitle:辽宁省49种降脂类药品的临床综合评价
- Author:
Jingwen GUO
1
;
Junlin CHEN
2
;
Xiuna LIANG
3
;
Shuang CAI
1
Author Information
1. Dept. of Pharmacy，the First Hospital of China Medical University，Shenyang 110001，China
2. School of Pharmacy，China Medical University，Shenyang 110122，China
3. School of Clinical Pharmacy，Shenyang Pharmaceutical University，Shenyang 110122，China
- Publication Type:Journal Article
- Keywords:
lipid-lowering drugs;
clinical comprehensive evaluation;
drug list;
safety;
effectiveness;
Liaoning province
- From:
China Pharmacy
2025;36(24):3041-3047
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To establish a comprehensive evaluation system for lipid-lowering drugs aligned with the clinical reality of Liaoning province， and to assess the commonly used lipid-lowering drugs in medical institutions within Liaoning province. METHODS A comprehensive evaluation system for lipid-lowering drugs of Liaoning province was established using literature analysis and the Delphi expert consultation method. A calculation method of “indicator weighted score” to “step-by-step aggregation” to “percentile standardization” was employed to enable horizontal comparison of 49 commonly used lipid-lowering drugs. RESULTS This study successfully established a comprehensive clinical evaluation system for lipid-lowering drugs of Liaoning province， comprising 7 first-level indicators， 35 second-level indicators， and 116 scoring criteria. Among the first-level indicators， effectiveness （23%） had the highest weight， followed sequentially by safety （22%）， innovativeness （15%）， economy （13%）， suitability （13%）， accessibility （10%）， and other attributes （4%）. Among the 49 evaluated lipid-lowering drugs， the top 10 in overall score were all statins， with rosuvastatin calcium tablet B having the highest total score of 79.22. Inclisiran sodium injection had a total score of 57.14， performed outstandingly in safety （16.27） and innovativeness （11.27）. CONCLUSIONS This study established a relatively comprehensive and detailed clinical evaluation system for lipid-lowering drugs of Liaoning province. Statins remain the cornerstone of lipid management. Most patients can primarily choose drugs like rosuvastatin tablet B， while PCSK9 inhibitors and fixed-dose combinations can be considered for patients with conventional treatment failure or statin intolerance.
